Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC57TE
|
|||
| Drug Name |
BT8009
|
|||
| Drug Type |
Bicycle?toxin conjugate
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
Bicycle Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nectin cell adhesion molecule 4 (NECTIN4) | Target Info | . | [2] |
| KEGG Pathway | Adherens junction | |||
| Reactome | Adherens junctions interactions | |||
| WikiPathways | Cell junction organization | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04561362) Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Bicycle Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.